Frailty conundrums: dilemmas and unsolved conceptual issues.

Similar documents
Frailty: Challenges and Possible Solutions

Translating pilot studies into larger clinical trials Twelve Commandments Marco Pahor, MD University of Florida Institute on Aging.

FRAILTY SYNDROME. dr. Rose Dinda Martini, Sp.PD, K-Ger

Endpoints And Indications For The Older Population

What is frailty and why it is important

Physical Function & Frailty in HIV

The LIFE Study. Marco Pahor, MD University of Florida Institute on Aging.

Modulate the prevention stategy according to the level of frailty. Prof Leocadio Rodríguez Mañas Hospital Universitario de Getafe

public health crisis! Understanding frailty at population level!

The Industry s Views on Older Old Patients

Integrating Geriatrics into Oncology Care

Protein Requirements for Optimal Health in Older Adults: Current Recommendations and New Evidence

SARCOPENIA FRAILTY AND PROTEINS

Frailty: from Academic Definition to Clinical Applicability

Pre- Cardiac intervention. Dr. Victor Sim 26 th Sept 2014

Implementing frailty into clinical practice:

Ageing Well. Avoiding falls in older people. Prof Martin Vernon NCD Older People. Find Recognise Assess Intervene Long-term.

ESPEN Congress The Hague 2017

Frailty Assessment: Simplifying the Complex

Pre- Cardiac intervention. Dr. Victor Sim 16 th Oct 2014

Geriatric Assessment & Intervention. The Goal 5/9/2017. Current events. Student Conclave 2017 Fresno State goo.gl/slides/m5d6wm.

Frailty Predicts Recurrent but Not Single Falls 10 Years Later in HIV+ and HIV- Women

Clinical Epidemiology of Frailty in HIV Infection. Joseph B. Margolick, MD, PhD Johns Hopkins Bloomberg School of Public Health

Frailty in Older Mexican Americans

HIV, Aging, and Frailty: Cannonball?

Identifying and Understanding Frailty

PHYSICAL FRAILTY & SARCOPENIA IN SPRINTT

Biological Correlates of Frailty in Older Heart Failure Patients

Edith Haage, PT, GCS NewCourtland Senior Services 10/26/2016. NEWCOURTLAND.org

Frailty Ascertainment: Beginning of the pathway to treatment

Biological theory for the construct of intrinsic capacity to be used in clinical settings Matteo Cesari, MD, PhD

Chairs: John Lainchbury & Andrew Aitken. Elderly/Frailty

Frailty and Depression in Late Life

Treatment of sarcopenia: latest developments. Dr Miles D Witham Clinical Reader in Ageing and Health University of Dundee.

Evaluation of fragility and factors influencing falls in nursing homes. Dr Marie-Laure Seux Geriatrics Broca Hospital May 2013

Prospective Evaluation of the Eyeball Test for Assessing Frailty in Elderly Patients with Valvular Heart Disease

Living well with frailty. JOHN YOUNG National Clinical Director for the Frail Elderly & Integration, NHS England

What is Frailty? National Background and Local Pathways

Clinical Treatment of Obesity in Older Women. Barbara Nicklas J. Paul Sticht Center on Aging

Frailty in Older Adults. Farshad Sharifi, MD, MPH Elderly Health Research Center

The Frail and At-Risk Critically Ill: Screening and Outcomes

Biomedical versus BioPsychosocial Model of Frailty

Older people are living longer than before, but are they living healthier?

HIV, Multimorbidity, and Frailty: what s going on? (with apologies to Marvin Gaye)

Sarcopenia una definicion en evolucion. Hélène Payette, PhD Centre de recherche sur le vieillissement

Ageing and frailty Facts and myths. Finn Rønholt MD. Ph.d. MPA.

Drug Side Effects That Mimic Aging

March 13, :00 11:00 a.m. CST. Jane F. Potter, MD

Frailty and Sarcopenia

FRAILTY AND COGNITION IN THE ASSESSMENT OF VASCULAR SUGERY PATIENTS WHY WHY DISCLOSURES. INDIVIDUAL None. INSTITUTIONAL Cook, Inc

General Conditioning for an Active Life. B. Jon Ellingworth P.T.

Services for Frailty or Services for Dementia? Dr Gill Turner Lymington New Forest

Stefano Volpato. Diagnosi e Trattamento della Sarcopenia nell Anziano

Screening and treatment of hypertension in older adults: less is more?

Economics of Frailty. Eamon O Shea

Geriatrics and Cancer Care

Population Division, DESA, United Nations: World Population Ageing

Improving the Survivorship of Older Adults with Cancer Using Geriatric Assessment

Cirrhosis: Let s get moving!

Continence, falls and the frailty syndrome. Anne Foley - BGS Bladders and Bowel Health 2012

The Deconditioned Elderly Patient: Have We Been Getting it Wrong? By: Ernest Roy PT, DPT

A Study of relationship between frailty and physical performance in elderly women

Interprofessional Care for Elders through 48/5

The Lifestyle Interventions and Independence for Elders Pilot (LIFE-P): 2-Year Follow-up

Strength Balance and Function in the Elderly

Sarcopenia and Frailty in Older People

Sleep and Falls. Katie L. Stone, Ph.D. October 4-6, 2015

Nutrition to prevent and treat sarcopenia in older people

Exploring muscle mass measurements that predict functional outcomes

The Korean version of the FRAIL scale: clinical feasibility and validity of assessing the frailty status of Korean elderly

Update on Frailty. Stephanie Studenski Longitudinal Studies Section Intramural Research Program National Institute on Aging

11/5/2011. Disclosure. Evidence Based Medicine (EBM) ADAPT Clinical Outcomes. 18-month Clinical Outcomes

Geriatric screening tools in older patients with cancer

Frailty and Cognitive Dysfunction in Heart Failure. Disclosures. Frailty 5/24/2017. I have no disclosures relevant to this presentation

Challenge: the elderly patient with cancer The physical therapists perspective

Frailty as deficit accumulation

Getting Fit for Transplant. Thuy Koll, MD Assistant Professor Division of Geriatrics Department of Internal Medicine

Frailty. Nicholas Butler MD, MBA Department of Family Medicine University of Iowa

Preoperative Assessment Guidelines in the Elderly

Frailty in Older Adults

Frailty as deficit accumulation

X-FILES in NUTRIZIONE CLINICA ed ARTIFICIALE

Statistical Considerations in Pilot Studies

On Bridging the Theory and Measurement of Frailty

FRAGILITÀ, DISABILITÀ E MALATTIE NELLO STUDIO PRO.V.A. Enzo Manzato (Padova)

Definition and Diagnosis of Sarcopenia for Asian the Basic Science

Comorbidities in Multiple Myeloma

Elderly patients with advanced frailty in the community: a qualitative study on their needs and experiences

Clinical utility of the concept of intrinsic capacity

PIs are the real world answer for the chronic patient s management. Giovanni Guaraldi

Frailty: what s it all about?

EXERCISE, PHYSICAL ACTIVITY, TRAINING AND AGING

7/12/2016. Presenter Disclosure Information. The Other Half of the Fracture Equation: Fall Prevention and Management. Presentation Outline

AN ABSTRACT OF THE DISSERTATION OF. Chenkai Wu for the degree of Doctor of Philosophy in Public Health presented on May 23, 2017

Frailty in Older Adults. Frailty

Old age, polymorbidity and stroke, a new epidemy?

4/26/2012. Laura Grooms, MD Assistant Professor Geriatric Medicine Department of Family and Geriatric Medicine University of Louisville April 20, 2012

Nutritional Assessment in frail elderly. M. Secher, G.Abellan Van Kan, B.Vellas 1st December 2010 Firenze

Kidney Transplant in the Elderly. Robert Santella, M.D., F.A.C.P.

An Ounce of Prevention: Using Resistance training to optimize function in (pre-)frailty

Transcription:

Roger A. Fielding, PhD Director and Senior Scientist Professor of Nutrition and Medicine Nutrition, Exercise Physiology, and Sarcopenia Laboratory Frailty conundrums: dilemmas and unsolved conceptual issues. WHO: Frailty Network Meeting Geneva, Switzerland Nov 2016 Tufts University, Jean Mayer United States Department of Agriculture Human Nutrition Research Center on Aging

Disclosures: Consultancies: Merck, Eli Lilly, Essentient, Regeneron, Dairy Management Inc., Nestle Inc. Advisory board memberships: Cytokinetics, Segterra, Aging in Motion, Myosyntax, Ammonett. Grant support: NIH (NIA, NHLBI, NIDDK), USDA, Department of Defense, Dairy Research Institute, Unilever, Nestle Inc., Regeneron.

Skeletal Muscle Matters! Makes up 45-50% of body mass Fundamental role in locomotion, O 2 consumption, whole-body energy metabolism, and substrate turnover and storage Secretory organ (myokines) Robust skeletal muscle is a central factor in whole-body health and essential for maintaining energy homeostasis Rivas & Fielding. Muscle. Encyclopedia of Human Nutrition (3 rd Ed.) 2012

Mobility across species Dickinson et al. Science 2000; 288:5463

Aging drosophila and performance Miller et al. Biophys J 2008;95:2391

HABC 400 m walk performance and mortality Newman et al. JAMA; 2006;295:2018

Sarcopenia: Age-associated loss in muscle mass and function Female 70 yrs. BMI = 23.3 Sarcopenia is a key biological component of the frailty syndrome Female 85 yrs. BMI = 24.6

Historic Alignment Worldwide of Societal, Governmental, and Pharmaceutical Industry Interest in Sarcopenia: Recognized priority area of research by NIA: NIA-PCORI Initiative STRIDE Study, LIFE Study. IMI EU initiative: SPRINT-T Trial. Increased international awareness of Sarcopenia: WCO, IFSCR. Multiple candidate molecules in early and mid-stage development targeting skeletal muscle dysfunction, sarcopenia, and ultimately frailty. October 2016 establishment of ICD-10 for Sarcopenia.

Behavioral Interventions to target Frailty

FRAILTY Frailty state of increased vulnerability to stressor events confering high risk for major negative outcomes, including disability, falls, fractures and mortality Consensus on its operationalization has not yet been achieved Most widely used definition operationalized by Fried et al. phenotype of frailty, validated in the CHS study, with the presence of 3 of 5 criteria denoting frailty (weight loss, self-reported exhaustion, low energy expenditure, slow gait speed, and weak grip strength) Clegg et al. Lancet 2013 Keevil et al. Proc Nutr Soc 2015 Fried et al. J Gerontol A Biol Sci Med Sci 2001

FRAILTY AND EXERCISE Simpler tool validated using data from the SOF study the SOF frailty index, with the presence of 2 criteria of 3 denoting frailty (weight loss, inability to rise from a chair 5 times without using arms, and self-reported reduced energy level) Predict risk of disability, falls, fracture, and mortality as well as the more complex Fried frailty index SOF frailty index does not integrate the level of physical activity, making this tool potentially more meaningful for the evaluation of physical activity-based interventions Ensrud et al. Arch Intern Med 2008

Lifestyle Interventions and Independence for Elders* Design: a Phase 3 RCT (LIFE-M) N = 1600 (8 clinical centers) Mean FU: 2.7 years (min 1.9 - max 3.9 years) Intervention: aerobic + resistance exercise vs. health education *Fielding et al. J. Gerontol. 2011

70-89 years Inclusion criteria Age 70-89 yrs Sedentary Able to walk 400 m SPPB score <9 (45% <7)

Tufts University BYMCU

Physical activity HR=0.82, 95%CI=0.69-0.98 p=0.03 Health Education Pahor et al JAMA 2014

BASELINE CHARACTERISTICS OF PARTICIPANTS BY RANDOMIZATION GROUPS AND FRAILTY STATUS Frail according to Fried index: 26.9 % (439/1635) Frail according to SOF index: 19.6% (321/1635) Physical activity (n=818) Health education (n=817) Frail (n=222) Not frail (n=596) All P Value Frail (n=217) Not frail (n=600) All P Value * Mean (SD) age, years 79.9 ± 5.4 78.2 ± 5.1 78.7 ± 5.2 <0.001 80.4 ± 5.3 78.6 ± 5.1 79.1 ± 5.2 <0.001 Female sex 165 (74%) 382 (64%) 547 (67%) 0.006 169 (78%) 382 (64%) 551 (67%) <0.001 Mean (SD) 3MSE, score 90.8 ± 5.7 91.8 ± 5.4 91.5 ± 5.5 0.020 90.7 ± 5.5 92.0 ± 5.2 91.6 ± 5.3 0.003 Mean (SD) CES-D, score 12.4 ± 9.3 6.9 ± 6.5 8.3 ± 7.7 <0.001 12.4 ± 8.8 7.6 ± 7.2 8.8 ± 7.9 <0.001 Mean (SD) number of chronic conditions 1.9 ± 1.2 1.7 ± 1.1 1.8 ± 1.1 0.028 2.1 ± 1.2 1.8 ± 1.1 1.8 ± 1.2 0.002 Mean (SD) SPPB, score 6.7 ± 1.8 7.7 ± 1.4 7.4 ± 1.6 <0.001 6.3 ± 1.7 7.7 ± 1.4 7.3 ± 1.6 <0.001 Mean (SD) number of Fried frailty index criteria 3.3 ± 0.5 1.4 ± 0.7 1.9 ± 1.0 <0.001 3.2 ± 0.4 1.4 ± 0.7 1.9 ± 1.0 <0.001 * Frail vs not frail subjects within group of randomization

INCIDENCE OF FIRST INITIAL FRAILTY ACCORDING TO RANDOMIZATION GROUP AT EACH VISIT Fried frailty index Physical activity (n=818) Health education (n=817) Baseline prevalence of frailty 222 (0.27) [0.24-0.30] 217 (0.27) [0.24-0.30] Baseline prevalence of not frailty 596 (0.73) [0.70-0.76] 600 (0.73) [0.70-0.77] Cumulative incidence Cumulative incidence 6 Month 54 (0.18) [0.13-0.23] 73 (0.24) [0.19-0.30] SOF frailty index 12 Month 24 Month 109 (0.20) [0.16-0.23] 154 (0.15) [0.13-0.18] 125 (0.22) [0.19-0.26] 177 (0.18) [0.15-0.20] Baseline prevalence of frailty 159 (0.19) [0.17-0.22] 162 (0.20) [0.17-0.23] Baseline prevalence of not frailty 659 (0.81) [0.78-0.83] 655 (0.80) [0.77-0.83] Cumulative incidence Cumulative incidence 6 Month 71 (0.22) [0.17-0.27] 102 (0.31) [0.25-0.37] 12 Month 127 (0.21) [0.17-0.24] 138 (0.23) [0.19-0.27] 24 Month 177 (0.16) [0.14-0.19] 195 (0.18) [0.15-0.20] Data are presented as n (count/person year) [95% CI for incidence]

GEE MODELS PREDICTING FRAILTY OVER 24 MONTHS ACCORDING TO RANDOMIZATION GROUP Unadjusted odds ratio (95% CI) P Value Adjusted odds ratio * (95% CI) P Value Fried frailty index Physical activity (n=818) 0.83 [0.69-0.99] 0.040 0.81 [0.68-0.98] 0.028 Health education (n=817) (Reference) SOF frailty index Physical activity (n=818) 0.81 [0.67-0.98] 0.034 0.86 [0.71-1.04] 0.125 Health education (n=817) (Reference) * Baseline value of the outcome, gender and field center (both used to stratify randomization), age, intervention, clinic visit, and intervention-by-visit interaction included in the models.

Mean Number of Frailty Criteria ESTIMATED EFFECTS OF THE INTERVENTION ON THE MEAN NUMBER OF FRIED FRAILTY CRITERIA 2 Average effect: P<0.001 1.9 Health education 1.8 1.7 1.6 1.5 1.4 P<0.001 P<0.003 P<0.001 1.3 1.2 Baseline Month 6 Month 12 Month 24

MAJOR MOBILITY DISABILITY AND PERSISTENT MAJOR MOBILITY DISABILITY OCCURRENCE IN FRAIL PARTICIPANTS AT BASELINE Major mobility disability* Persistent mobility disability HR=0.69 [CI, 0.49-0.98]; P=0.04 HR=0.58 [CI, 0.39-0.91]; P=0.01 Overall, the interaction term between frailty and randomization arm was not significant for major mobility disability outcome (P=0.31).

Summary: Age-associated skeletal muscle dysfunction (Sarcopenia) is a key biological mediator of the frailty syndrome. 24 months of a structured, moderateintensity physical activity program significantly reduced the risk and severity of frailty. Among frail individuals, the risk of major mobility disability was reduced by 31% with the physical activity intervention, while falls and fractures risks were not modified. These results stress the need to engage even the more frail individuals in such programs. Function promoting anabolic therapies should be evaluated with respect to their efficacy in both non-frail and frail older adults.

The Disablement Pathway*, Intrinsic Capacity, Frailty, and Sarcopenia Pathology: reduced muscle size, neural activation/recruitment, mitochondrial function, local vascular change (WHO: Body Function, Structure) Impairment: muscle strength/power, aerobic/endurance capacity Intrinsic Capacity Functional Limitation*: gait speed, chair rise time (WHO: Activity) Functional Ability Disability*: role limitations (WHO: Participation) *Nagi, 1965; Verbrugge & Jette, 1994

Prevalence (%) 100 90 80 70 60 50 40 30 20 10 ESTIMATED EFFECTS OF THE INTERVENTION ON THE PREVALENCE OF EACH OF FRIED Average effect: P<0.001 AND SOF FRAILTY CRITERION Average effect: P<0.004 Baseline Month 6 Month 12 Month 24 0 PA HE PA HE PA HE PA HE PA HE PA HE PA HE Fried Exhaustion PA = Physical activity Fried Sedentariness HE = Health education Fried Slow gait speed Fried Poor muscle strength Fried / SOF Weight loss SOF Inability to rise from a chair 5 times SOF Reduced energy level